Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

Immunicum's cell therapy misses survival endpoint in Phase II RCC trial
Immunicum AB (SSE:IMMU) lost SEK1.46 (14%) to SEK8.86 after reporting that ilixadencel plus Sutent sunitinib from

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE